At the upcoming 65th American Society of Hematology (ASH) Annual Meeting, AstraZeneca will present a wealth of new clinical and real-world data spanning multiple hematological disorders. This presentation will comprise a substantial 63 abstracts highlighting 14 approved and innovative medications within the company’s extensive portfolio, including their group focusing on rare diseases, Alexion.

Significant among the data presented will be six-year follow-up results from the ELEVATE-TN Phase III trial, which is anticipated to reinforce the long-term efficacy and safety of CALQUENCE (acalabrutinib) in patients with chronic lymphocytic leukemia (CLL) who have not undergone previous treatment. Moreover, in the realm of paroxysmal nocturnal hemoglobinuria (PNH), the ALPHA Phase III trial is set to reveal the potential of danicopan to manage clinically significant extravascular hemolysis effectively.

Anas Younes, Senior Vice President of Hematology R&D at AstraZeneca, and Gianluca Pirozzi, Senior Vice President at Alexion, emphasized the company’s commitment to advancing care in hematology through innovative therapies like T-cell engagers, antibody-drug conjugates, and other novel scientific approaches.

These updates highlight AstraZeneca’s strategic efforts to drive advancements across various stages of drug development and spotlight their leadership role in addressing hematological malignancies and other blood disorders.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.